BeiGene Ltd ADR (BGNE)

BeiGene shares price target raised on Brukinsa robust launch - Investing.com

Investing.com

BeiGene stock price target lowered by Jefferies despite sales growth - Investing.com

Investing.com

BeiGene shares edge up on narrower-than-expected loss in Q1, revenue beat - Investing.com

Investing.com

BeiGene shares get price target bump on recent collaboration developments By Investing.com - Investing.com UK

Investing.com UK

Evaluating BeiGene: Insights From 6 Financial Analysts

Benzinga

BeiGene Ltd ADR [BGNE] Investment Appeal on the Rise – Knox Daily - Knox Daily

Knox Daily

BeiGene CEO John Oyler sells shares worth over $7.4 million - Investing.com

Investing.com

4 Analysts Assess BeiGene: What You Need To Know

Benzinga

Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Benzinga

BofA raises BeiGene stock target to $179.30 on strong drug sales growth - Investing.com

Investing.com

BeiGene CEO John Oyler sells shares worth over $8.3 million - Investing.com

Investing.com

Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session

Benzinga

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

Seeking Alpha

UBS cuts BeiGene stock target to $285.70, maintains Buy rating - Investing.com

Investing.com

BeiGene reports Q4 earnings beat, record annual revenue - Investing.com

Investing.com

BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?

Zacks Investment Research

BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards? - Nasdaq

Nasdaq

JP Morgan's Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point

Benzinga

5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond

The Motley Fool

As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks?

Benzinga

3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024

Zacks Investment Research

Top 5 Momentum Picks for January After a Fabulous 2023

Zacks Investment Research

New Strong Buy Stocks for December 22nd

Zacks Investment Research

3 Cancer-Focused Biotechs That Appear Promising Bets for 2024

Zacks Investment Research

5 Nasdaq Composite Laggards Likely to Gather Pace in 2024

Zacks Investment Research

The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics

Zacks Investment Research

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

Zacks Investment Research

Primecap Odyssey Funds' 2023 Semiannual Letter - GuruFocus.com

GuruFocus.com

Weekly Upgrades and Downgrades - InvestorPlace

InvestorPlace

BeiGene shares drop after AbbVie unit files patent-infringement lawsuit over cancer drug - MarketWatch

MarketWatch

Making it harder to "buy" China, Inc. | US-China Institute - US-China Institute

US-China Institute

What Happens to Your ETFs if Chinese ADRs Delist? - Morningstar HK

Morningstar HK

Are Delistings of Chinese Stocks on Their Way? - Morningstar

Morningstar

US-Listed Chinese Companies React To Today's HFCAA Announcement & Fading Optimisim On Ukraine Truce - Forbes

Forbes

BeiGene stock: Buy or sell China's cancer-fighting Pharma giant? - Asia Markets

Asia Markets

Novartis (NVS) Collaborates With BeiGene for Oncology Drug - Yahoo Movies UK

Yahoo Movies UK

See What the Public Investment Fund Bought Recently Including Walmart and FedEx Stocks - SWFI - Sovereign Wealth Fund Institute

Sovereign Wealth Fund Institute

Dow Jones Industrial Average Futures Drop After ADP Payrolls Miss - Schaeffers Research

Schaeffers Research